Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin plus Ningmitai for benign prostatic hyperplasia (double-blind RCT)
ChiCTR2200060060Phase 4Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of silodosin and ningmitai in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Xiyuan Hospital. Primary endpoints: International Prostate Symptom Score and Maximum urine flow rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
silodosinningmitai
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on ChiCTR2200060060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060060.